In contrast, all NRASQ61 mutated cell lines were sensitive to the MEK inhibitor (MEKi) trametinib at low nanomolar concentrations, highlighting the importance of MEK signaling in RAS mutant cancer. The gene discussed is MAP2K7; the disease is cancer.